Tumor
lysis syndrome is a potentially fatal complication of oncological therapy.
Atezolizumab is a recently-approved agent for the treatment of advanced
urothelial carcinoma and, to the best of our knowledge, tumor lysis syndrome
has never been reported after atezolizumab therapy for urothelial carcinoma.
We present the
case of a 77-year-old female who developed acute renal failure and tumor lysis
syndrome after a single infusion of atezolizumab for metastatic urothelial
carcinoma involving both upper and lower tract.
